Concepedia

Julio Rosenstock

JR

271

Publications

50.6K

Citations

110

H-Index

1985

Active since

Affiliations

Dallas Diabetes Research Center(Current)

The University of Texas Southwestern Medical Center

Novo Nordisk (Denmark)

Boehringer Ingelheim (Germany)

Eli Lilly (United States)

Julio Rosenstock is an author at Dallas Diabetes Research Center specializing in medicine, diabetes, and metabolic syndrome.

Top concepts

DiabetesMedicineMetabolic SyndromePharmacologyCardiovascular DiseaseHealthPharmacotherapyPhysiologyPublic HealthHealth Policy

Publications per year

1985–2025

271

Publications

271

Once-Weekly Semaglutide in Adults with Overweight or Obesity

John Wilding, Rachel L. Batterham, Salvatore Calanna et al. · New England Journal of Medicine · 2021 · 3.9K citations

Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial

Hertzel C. Gerstein, Helen M. Colhoun, Gilles R. Dagenais et al. · The Lancet · 2019 · 2.8K citations · Full text

Metabolic Syndrome, Diabetes Management, Cardiovascular Disease +9

Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes

Juan P. Frías, Melanie J. Davies, Julio Rosenstock et al. · New England Journal of Medicine · 2021 · 1.7K citations

Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6)

John B. Buse, Julio Rosenstock, Giorgio Sesti et al. · The Lancet · 2009 · 1.5K citations

Open-label Trial, Diabetes Management, Medicine +6

The Treat-to-Target Trial

Matthew C. Riddle, Julio Rosenstock, John Gerich · Diabetes Care · 2003 · 1.5K citations · Full text

Rows per page

1–5 of 271